Oncology

Latest News

Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health

How to Choose Between Fixed-Duration vs Continuous BTKi Therapy for CLL

By Pearl Steinzor

December 10th 2024

Sophia Humphreys, PharmD, MHA, BCBBS, a practicing pharmacist and health system director at Sutter Health, discussed the decision-making process for selecting between fixed-duration options and continuous Bruton tyrosine kinase inhibitor (BTKi) therapy for patients with chronic lymphocytic leukemia (CLL).

Person fills prior authorization form - Maksim Shchur - stock.adobe.com.jpeg

Prior Authorization Delays Cause Serious Harm to Patients With Cancer

By Pearl Steinzor

December 4th 2024

Highlights From ACCC Annual Meeting & Cancer Center Business Summit

ICYMI: Highlights From ACCC Spring 2024

By Pearl Steinzor

December 4th 2024

FDA approval. | Image Credit: syahrir - stock.adobe.com

FDA Approves Zanidatamab-hrii for HER2+ Biliary Tract Cancer

By Cameron Santoro

November 21st 2024

Non-Hodgkin Lymphoma | Image Credit: © MQ-Illustrations - stock.adobe.com

Drivers of Aggression Identified in Double-Expressor DLBCL

By Jared Kaltwasser

November 19th 2024

Join this panel as they discuss treatment for metastatic NSCLC patients without driver mutations.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

...

177 178 179 180 181

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions